Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Plasticity of Lineage and Immune Evasion in Primary SCLC and Transformation from LUAD to SCLC: Loss of Antigen Presentation and Shifts in Therapeutic Strategies

  • By

  • Hongying Xu

  • Benhua Li

  • Jun Yang

  • Xin Tang

  • September 4, 2026

Share

Original Source(s)

Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection

  • by Hongying Xu, Benhua Li, Jun Yang, Xin Tang

  • September 4, 2026

Related Content

Toward Precision Cardio-Oncology in Breast Radiotherapy

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min
Correction: Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer